Bioptimus

The company develops multimodal AI foundation models, such as H-Optimus and M-Optimus, that integrate histology, spatial transcriptomics, and genomics data to predict biological outcomes. These models are used for drug target and biomarker discovery, clinical trial design, and predicting treatment responses by analyzing archival patient data and clinical records. Their primary customers include pharmaceutical companies, clinical practices, and research institutions seeking to identify patient subsets and improve drug development success rates.